Bausch + Lomb and Celldex each reported phase 2 failures, but the outcomes had different strategic consequences. Celldex ended development of barzolvolimab in atopic dermatitis after the anti-KIT antibody failed to beat placebo on the trial’s primary endpoint and also missed key secondary endpoints.
Bausch + Lomb’s BL1332 missed the FDA-recommended primary endpoint in patients with pain following photorefractive keratectomy surgery, yet the company argued that consistent numerical advantages across primary, secondary and exploratory measures justify regulatory discussions before making a go/no-go decision. The split response shows how companies can treat a miss differently depending on how much residual signal they believe remains in the dataset.
The data
Celldex tested barzolvolimab against placebo in people with moderate-to-severe atopic dermatitis. At Week 16, the percentage change from baseline in the weekly average of the daily peak itch score was statistically no better on barzolvolimab than on placebo, meaning the study missed its primary endpoint. The trial also missed key secondary endpoints. Celldex said the study showed some undefined benefit, but the improvements did not meet its threshold for continued development in the indication.
The result adds to pressure on the mast-cell hypothesis Celldex had been pursuing in itchy skin diseases. The company had targeted atopic dermatitis and prurigo nodularis based on evidence that mast cells, which barzolvolimab depletes, drive itching in both conditions. After a phase 2 prurigo nodularis failure in July, TD Cowen analysts had already lowered expectations for the atopic dermatitis readout.
Bausch + Lomb evaluated BL1332, a topical TRPV1 antagonist, in the same general phase of development but in a different setting: pain after photorefractive keratectomy surgery. Neither dose beat vehicle control significantly on the sum of pain intensity differences over 24 hours, the primary endpoint. Even so, the company said BL1332 performed numerically better on primary, secondary and exploratory assessments. Chief medical officer Yehia Hashad said both dose groups showed numerically greater pain relief than vehicle across all pain measures evaluated, that more patients achieved complete pain relief following surgery and that the study produced evidence of faster corneal healing.
What the results change
Celldex’s decision was immediate and narrow. It is stopping development in atopic dermatitis while continuing to work toward a planned filing for approval in chronic spontaneous urticaria next year. That keeps investor attention on a program that already posted phase 3 wins in CSU in September, although the company’s stock fell at that time amid concerns about anaphylaxis.
For Bausch + Lomb, the next move is regulatory rather than developmental. Hashad said on an investor call that the company will need about six months to fully analyze the data and prepare briefing packages. He declined to say when a go/no-go decision will come, saying that timing will depend on talks with regulatory authorities. Senior vice president of R&D Mayssa Attar said the company wants to discuss measures beyond SPID with the FDA, including being pain-free, which she said is meaningful to patients.
The broader signal is that not all phase 2 misses are treated as equal. Celldex read its dataset as insufficient to justify more spending in atopic dermatitis. Bausch + Lomb is instead trying to determine whether endpoint selection, rather than a total absence of activity, is the more important issue for BL1332.




